3654 results for «392»

Filter By

3654 results

Personalised Vascular Care Award - Ceremony

20 May 2026 – From EuroPCR 2026

The Personalised Vascular Care Award Ceremony celebrated outstanding achievements in the advancement of personalized vascular treatment approaches, recognizing leaders who have contributed significantly to improving patient outcomes in vascular care.

Personalised Vascular Care Award - Ceremony

EuroPCR 2026 Closing Ceremony

22 May 2026 – From EuroPCR 2026

The EuroPCR 2026 Closing Ceremony marks the conclusion of this premier cardiology event, celebrating the latest advances and achievements in interventional cardiology. It offers an opportunity to reflect on the educational sessions, network with peers, and recognize outstanding contributions to the field.

EuroPCR 2026 Closing Ceremony

Welcome to EuroPCR 2026

19 May 2026 – From EuroPCR 2026

Welcome to EuroPCR 2026, the premier event for interventional cardiology professionals. This edition offers cutting-edge scientific presentations, live cases, and interactive sessions designed to advance knowledge and clinical practice in cardiovascular interventions.

Welcome to EuroPCR 2026

New frontiers in coronary disease treatment

21 May 2026 – From EuroPCR 2026

Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.

Pharmacology without borders, from coronary artherostenosis to radial artery

21 May 2026 – From EuroPCR 2026

This session delves into the expansive role of pharmacology in interventional cardiology, addressing topics ranging from coronary atherostenosis to radial artery management. Key discussions include the real-world efficacy and safety of intravenous cangrelor-assisted PCI in chronic coronary syndromes, comparative analysis of intra-arterial verapamil versus placebo for...

Focus on heart failure: from acute to chronic

21 May 2026 – From EuroPCR 2026

This comprehensive session delves into the spectrum of heart failure management, from acute presentations to chronic conditions. Key topics include the cardio-hepatic syndrome and right ventricular dysfunction in HFmrEF, prognostic implications of heart failure etiologies, and innovative approaches such as AI-assisted echocardiography for early detection of...

Strategies to enhance bifurcation PCI outcomes

21 May 2026 – From EuroPCR 2026

This session addresses strategies to optimize outcomes in coronary bifurcation PCI. It evaluates the impact of cutting and scoring balloons versus non-compliant balloons on stent expansion, predictors of target vessel revascularization using the POKI technique, and compares stent and non-stent approaches in side branch myocardial infarction...

Aortic stenosis: from diagnostic to treatment

21 May 2026 – From EuroPCR 2026

This session provides an in-depth review of contemporary management of aortic stenosis, covering diagnostic advancements, temporal trends, and treatment outcomes. It includes insights from the LAPLACE-TAVI registry focusing on low-risk patients, discusses the growing feasibility of day-case TAVI procedures, compares transcatheter and surgical valve replacements in...

Why hypertension is a major unresolved problem

02 Oct 2024

Explore the global challenge of hypertension, affecting one in three adults, and the strategies for screening, diagnosis, and management, including lifestyle modifications, pharmacotherapy, and device-based treatments, as outlined by Sofie Brouwers.

Sofie Brouwers

Author

Sofie Brouwers
Why hypertension is a major unresolved problem

BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

07 Nov 2022

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Nicola Ryan

Author

Nicola Ryan
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

TRISCEND II: Two-year outcomes of transcatheter tricuspid valve replacement for severe tricuspid regurgitation

31 Mar 2026

Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.

Jonathan Curio

Author

Jonathan Curio
TRISCEND II: Two-Year Outcomes Of Transcatheter Tricuspid Valve Replacement For Severe Tricuspid Regurgitation

Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

08 Jan 2025

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author

Bruno Scheller
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

Evidence base: A description of the key, so far published, studies in the space of drug coated balloons

23 Jan 2025

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Author

Hector Garcia-Garcia
Jorge Sanz Sanchez

Author

Jorge Sanz-Sanchez
Evidence base: A description of the key, so far published, studies in the space of drug coated balloons

NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome

02 Sep 2025

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Daniele Giacoppo

Author

Daniele Giacoppo
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
Didn’t find what you were looking for?